MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Némoz, G.
Right arrow Articles by Conti, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Némoz, G.
Right arrow Articles by Conti, M.

0026-895X/97/020242-08$3.00/0
Copyright © by The American Society for Pharmacology and Experimental Therapeutics
All rights of reproduction in any form reserved.
MOLECULAR PHARMACOLOGY 51:242-249 (1997).

Selective Activation of Rolipram-Sensitive, cAMP-Specific Phosphodiesterase Isoforms by Phosphatidic Acid

Georges Némoz, Claudio Sette, and Marco Conti

Unité 352 Institut National de la Santé et de la Recherche Médicale, Biochimie et Pharmacologie Institut National des Sciences Appliquées-Lyon, 69621 Villeurbanne, France (G.N.), and Division of Reproductive Biology, Department of Gynecology and Obstetrics, Stanford University School of Medicine, Stanford, California 94305 (C.S., M.C.)

In rat thymic lymphocytes, accumulation of phosphatidic acid (PA) occurs at the same time as decrease in cAMP levels and activation of a cAMP-specific phosphodiesterase (PDE) [type 4, EC 3.1.4.17 (PDE4)]. We investigated the nature of the PDE activated by PA and the mechanism of activation by using recombinant cAMP-specific PDE4 isoforms derived from three different genes (PDE4A, PDE4B, and PDE4D). The "long" variants expressed from each gene (PDE4A5, PDE4B1, and PDE4D3) were activated by PA, whereas the "short" variants (PDE4A1, PDE4B2, PDE4D1, and PDE4D2) were not. Phosphatidylserine was an activator that was as effective as PA, whereas phosphatidylcholine was ineffective, indicating that activation was restricted to anionic phospholipids. PA caused an increase in the Vmax value of PDE4D3 without affecting the Km value of the enzyme for the cAMP substrate. PA also caused a change in the Mg2+ requirement for hydrolysis. Half-maximal stimulation of the PDE was obtained with ~10 µg/ml PA. Although protein kinase A-mediated phosphorylation of PDE4D3 produces effects similar to those elicited by PA, the mechanism of PA-induced activation was not found to involve a phosphorylation. Instead, several observations suggest that PA may directly interact with the enzyme. The stimulation of cAMP PDEs by PA and other acidic phospholipids may be a mechanism by which growth factors and hormones modulate the cAMP-dependent signal transduction pathway during cell stimulation.


Copyright © by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Circ. Res.Home page
K. Omori and J. Kotera
Overview of PDEs and Their Regulation
Circ. Res., February 16, 2007; 100(3): 309 - 327.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Conti, W. Richter, C. Mehats, G. Livera, J.-Y. Park, and C. Jin
Cyclic AMP-specific PDE4 Phosphodiesterases as Critical Components of Cyclic AMP Signaling
J. Biol. Chem., February 14, 2003; 278(8): 5493 - 5496.
[Full Text] [PDF]


Home page
J. Biol. Chem.Home page
G. S. Baillie, E. Huston, G. Scotland, M. Hodgkin, I. Gall, A. H. Peden, C. MacKenzie, E. S. Houslay, R. Currie, T. R. Pettitt, et al.
TAPAS-1, a Novel Microdomain within the Unique N-terminal Region of the PDE4A1 cAMP-specific Phosphodiesterase That Allows Rapid, Ca2+-triggered Membrane Association with Selectivity for Interaction with Phosphatidic Acid
J. Biol. Chem., July 26, 2002; 277(31): 28298 - 28309.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
K.-i. Nakajima, H. Sonoda, T. Mizoguchi, J. Aoki, H. Arai, M. Nagahama, M. Tagaya, and K. Tani
A Novel Phospholipase A1 with Sequence Homology to a Mammalian Sec23p-interacting Protein, p125
J. Biol. Chem., March 22, 2002; 277(13): 11329 - 11335.
[Abstract] [Full Text] [PDF]


Home page
Mol. Biol. CellHome page
F. Naro, C. Sette, E. Vicini, V. De Arcangelis, M. Grange, M. Conti, M. Lagarde, M. Molinaro, S. Adamo, and G. Némoz
Involvement of Type 4 cAMP-Phosphodiesterase in the Myogenic Differentiation of L6 Cells
Mol. Biol. Cell, December 1, 1999; 10(12): 4355 - 4367.
[Abstract] [Full Text]


Home page
J. Lipid Res.Home page
S. Bechoua, M. Dubois, G. Némoz, M. Lagarde, and A.-F. Prigent
Docosahexaenoic acid lowers phosphatidate level in human activated lymphocytes despite phospholipase D activation
J. Lipid Res., April 1, 1998; 39(4): 873 - 883.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
M. Grange, C. Sette, M. Cuomo, M. Conti, M. Lagarde, A.-F. Prigent, and G. Nemoz
The cAMP-specific Phosphodiesterase PDE4D3 Is Regulated by Phosphatidic Acid Binding. CONSEQUENCES FOR cAMP SIGNALING PATHWAY AND CHARACTERIZATION OF A PHOSPHATIDIC ACID BINDING SITE
J. Biol. Chem., October 20, 2000; 275(43): 33379 - 33387.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1997 by the American Society for Pharmacology and Experimental Therapeutics